| 產(chǎn)品名稱 |
2AB1-IA10 |
| 商品貨號 |
B163671 |
| Organism |
Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The antibody reacts with laminin and can be used to detect laminin in tissues, and for isolation and quantitation of laminin. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against laminin (basement membrane glycoprotein) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against laminin (basement membrane glycoprotein) |
| Comments |
Animals were immunized with extracellular matrix proteins from M1536-B3 cells. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody reacts with laminin and can be used to detect laminin in tissues, and for isolation and quantitation of laminin. |
| Complete Growth Medium |
Culture Medium: Alpha minimum essential medium (Eagle), 90%; heat-inactivated
horse serum, 10%. |
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Isotype |
IgG2b |
| Name of Depositor |
University of Pittsburgh |
| Deposited As |
rat (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Chung AE. Novel hybridoma cell line producing monoclonal antibodies against laminin and a process for the production thereof. US Patent 4,642,293 dated Feb 10 1987
|
